|

Defactinib Clinical Trials

10 actively recruiting trials across 6 locations

Also known as: PF-04554878, VS-6063, defactinib (VS-6063)

Other2 trials

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Phase 1/2
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
Phase 1

Atlanta, Georgia2 trials

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

Emory Winship Cancer Institute

Phase 2
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Emory University Hospital Midtown

Phase 2

Basking Ridge, New Jersey2 trials

A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2
A Study of Avutometinib and Defactinib in People With Thyroid Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Phoenix, Arizona1 trial

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

HonorHealth

Phase 3

Iowa City, Iowa1 trial

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

University of Iowa

Phase 1/2

New York, New York1 trial

Avutometinib and Defactinib in Diffuse Gastric Cancer

Columbia University Irving Medical Center

Phase 2

Houston, Texas1 trial

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

MD Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.